Logo of jcinvestThe Journal of Clinical InvestigationCurrent IssueArchiveSubscriptionAbout the Journal
J Clin Invest. 1991 Dec; 88(6): 2095–2105.
PMCID: PMC295810

Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure.


Studies of the mode of action of the bisphosphonate alendronate showed that 1 d after the injection of 0.4 mg/kg [3H]alendronate to newborn rats, 72% of the osteoclastic surface, 2% of the bone forming, and 13% of all other surfaces were densely labeled. Silver grains were seen above the osteoclasts and no other cells. 6 d later the label was 600-1,000 microns away from the epiphyseal plate and buried inside the bone, indicating normal growth and matrix deposition on top of alendronate-containing bone. Osteoclasts from adult animals, infused with parathyroid hormone-related peptide (1-34) and treated with 0.4 mg/kg alendronate subcutaneously for 2 d, all lacked ruffled border but not clear zone. In vitro alendronate bound to bone particles with a Kd of approximately 1 mM and a capacity of 100 nmol/mg at pH 7. At pH 3.5 binding was reduced by 50%. Alendronate inhibited bone resorption by isolated chicken or rat osteoclasts when the amount on the bone surface was around 1.3 x 10(-3) fmol/microns 2, which would produce a concentration of 0.1-1 mM in the resorption space if 50% were released. At these concentrations membrane leakiness to calcium was observed. These findings suggest that alendronate binds to resorption surfaces, is locally released during acidification, the rise in concentration stops resorption and membrane ruffling, without destroying the osteoclasts.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (4.7M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Smith R, Russell RG, Bishop M. Diphosphonates and Page's disease of bone. Lancet. 1971 May 8;1(7706):945–947. [PubMed]
  • Meunier PJ, Chapuy MC, Alexandre C, Bressot C, Edouard C, Vignon C, Mathieu L, Trechsel U. Effects of disodium dichloromethylene diphosphonate on Paget's disease of bone. Lancet. 1979 Sep 8;2(8141):489–492. [PubMed]
  • Frijlink WB, Bijvoet OL, te Velde J, Heynen G. Treatment of Paget's disease with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.). Lancet. 1979 Apr 14;1(8120):799–803. [PubMed]
  • Russell RG, Smith R, Preston C, Walton RJ, Woods CG. Diphosphonates in Paget's disease. Lancet. 1974 May 11;1(7863):894–898. [PubMed]
  • Canfield R, Rosner W, Skinner J, McWhorter J, Resnick L, Feldman F, Kammerman S, Ryan K, Kunigonis M, Bohne W. Diphosphonate therapy of paget's disease of bone. J Clin Endocrinol Metab. 1977 Jan;44(1):96–106. [PubMed]
  • Douglas DL, Duckworth T, Russell RG, Kanis JA, Preston CJ, Preston FE, Prenton MA, Woodhead JS. Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease. Lancet. 1980 May 17;1(8177):1043–1047. [PubMed]
  • Harinck HI, Papapoulos SE, Blanksma HJ, Moolenaar AJ, Vermeij P, Bijvoet OL. Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD). Br Med J (Clin Res Ed) 1987 Nov 21;295(6609):1301–1305. [PMC free article] [PubMed]
  • Pedrazzoni M, Palummeri E, Ciotti G, Davoli L, Pioli G, Girasole G, Passeri M. Short-term effects on bone and mineral metabolism of 4-amino-1-hydroxybutylidene-1,1-diphosphonate (ABDP) in Paget's disease of bone. Bone Miner. 1989 Nov;7(3):301–307. [PubMed]
  • Stone MD, Hawthorne AB, Kerr D, Webster G, Hosking DJ. Treatment of Paget's disease with intermittent low-dose infusions of disodium pamidronate (APD). J Bone Miner Res. 1990 Dec;5(12):1231–1235. [PubMed]
  • O'Doherty DP, Bickerstaff DR, McCloskey EV, Hamdy NA, Beneton MN, Harris S, Mian M, Kanis JA. Treatment of Paget's disease of bone with aminohydroxybutylidene bisphosphonate. J Bone Miner Res. 1990 May;5(5):483–491. [PubMed]
  • Adami S, Salvagno G, Guarrera G, Montesanti F, Garavelli S, Rosini S, Lo Cascio V. Treatment of Paget's disease of bone with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate. Calcif Tissue Int. 1986 Oct;39(4):226–229. [PubMed]
  • van Holten-Verzantvoort AT, Bijvoet OL, Cleton FJ, Hermans J, Kroon HM, Harinck HI, Vermey P, Elte JW, Neijt JP, Beex LV, et al. Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment. Lancet. 1987 Oct 31;2(8566):983–985. [PubMed]
  • Morton AR, Cantrill JA, Pillai GV, McMahon A, Anderson DC, Howell A. Sclerosis of lytic bone metastases after disodium aminohydroxypropylidene bisphosphonate (APD) in patients with breast carcinoma. BMJ. 1988 Sep 24;297(6651):772–773. [PMC free article] [PubMed]
  • Elomaa I, Blomqvist C, Porkka L, Holmström T, Taube T, Lamberg-Allardt C, Borgström GH. Clodronate for osteolytic metastases due to breast cancer. Biomed Pharmacother. 1988;42(2):111–116. [PubMed]
  • Merlini G, Parrinello GA, Piccinini L, Crema F, Fiorentini ML, Riccardi A, Pavesi F, Novazzi F, Silingardi V, Ascari E. Long-term effects of parenteral dichloromethylene bisphosphonate (CL2MBP) on bone disease of myeloma patients treated with chemotherapy. Hematol Oncol. 1990 Jan-Feb;8(1):23–30. [PubMed]
  • Attardo-Parrinello G, Merlini G, Pavesi F, Crema F, Fiorentini ML, Ascari E. Effects of a new aminodiphosphonate (aminohydroxybutylidene diphosphonate) in patients with osteolytic lesions from metastases and myelomatosis. Comparison with dichloromethylene diphosphonate. Arch Intern Med. 1987 Sep;147(9):1629–1633. [PubMed]
  • Siris ES, Sherman WH, Baquiran DC, Schlatterer JP, Osserman EF, Canfield RE. Effects of dichloromethylene diphosphonate on skeletal mobilization of calcium in multiple myeloma. N Engl J Med. 1980 Feb 7;302(6):310–315. [PubMed]
  • Jung A. Comparison of two parenteral diphosphonates in hypercalcemia of malignancy. Am J Med. 1982 Feb;72(2):221–226. [PubMed]
  • Sleeboom HP, Bijvoet OL, van Oosterom AT, Gleed JH, O'Riordan JL. Comparison of intravenous (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate and volume repletion in tumour-induced hypercalcaemia. Lancet. 1983 Jul 30;2(8344):239–243. [PubMed]
  • Percival RC, Paterson AD, Yates AJ, Beard DJ, Douglas DL, Neal FE, Russell RG, Kanis JA. Treatment of malignant hypercalcaemia with clodronate. Br J Cancer. 1985 May;51(5):665–669. [PMC free article] [PubMed]
  • Ralston SH, Gardner MD, Dryburgh FJ, Jenkins AS, Cowan RA, Boyle IT. Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia. Lancet. 1985 Oct 26;2(8461):907–910. [PubMed]
  • Ralston SH, Gallacher SJ, Patel U, Dryburgh FJ, Fraser WD, Cowan RA, Boyle IT. Comparison of three intravenous bisphosphonates in cancer-associated hypercalcaemia. Lancet. 1989 Nov 18;2(8673):1180–1182. [PubMed]
  • Davis JR, Heath DA. Comparison of different dose regimes of aminohydroxypropylidene-1,1-bisphosphonate (APD) in hypercalcaemia of malignancy. Br J Clin Pharmacol. 1989 Sep;28(3):269–274. [PMC free article] [PubMed]
  • Valkema R, Vismans FJ, Papapoulos SE, Pauwels EK, Bijvoet OL. Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD. Bone Miner. 1989 Jan;5(2):183–192. [PubMed]
  • Reid IR, King AR, Alexander CJ, Ibbertson HK. Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Lancet. 1988 Jan 23;1(8578):143–146. [PubMed]
  • Reid IR, Schooler BA, Stewart AW. Prevention of glucocorticoid-induced osteoporosis. J Bone Miner Res. 1990 Jun;5(6):619–623. [PubMed]
  • Reginster JY, Lecart MP, Deroisy R, Sarlet N, Denis D, Ethgen D, Collette J, Franchimont P. Prevention of postmenopausal bone loss by tiludronate. Lancet. 1989 Dec 23;2(8678-8679):1469–1471. [PubMed]
  • Storm T, Thamsborg G, Steiniche T, Genant HK, Sørensen OH. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med. 1990 May 3;322(18):1265–1271. [PubMed]
  • Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Licata AA, Ross P, Woodson GC, 3rd, Yanover MJ, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med. 1990 Jul 12;323(2):73–79. [PubMed]
  • Fleisch H, Russell RG, Francis MD. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science. 1969 Sep 19;165(3899):1262–1264. [PubMed]
  • Boonekamp PM, van der Wee-Pals LJ, van Wijk-van Lennep MM, Thesing CW, Bijvoet OL. Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner. 1986 Feb;1(1):27–39. [PubMed]
  • Flanagan AM, Chambers TJ. Dichloromethylenebisphosphonate (Cl2MBP) inhibits bone resorption through injury to osteoclasts that resorb Cl2MBP-coated bone. Bone Miner. 1989 Apr;6(1):33–43. [PubMed]
  • Carano A, Teitelbaum SL, Konsek JD, Schlesinger PH, Blair HC. Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J Clin Invest. 1990 Feb;85(2):456–461. [PMC free article] [PubMed]
  • Löwik CW, van der Pluijm G, van der Wee-Pals LJ, van Treslong-De Groot HB, Bijvoet OL. Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts: the effect of a bisphosphonate. J Bone Miner Res. 1988 Apr;3(2):185–192. [PubMed]
  • Cecchini MG, Felix R, Fleisch H, Cooper PH. Effect of bisphosphonates on proliferation and viability of mouse bone marrow-derived macrophages. J Bone Miner Res. 1987 Apr;2(2):135–142. [PubMed]
  • Hughes DE, MacDonald BR, Russell RG, Gowen M. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest. 1989 Jun;83(6):1930–1935. [PMC free article] [PubMed]
  • Papapoulos SE, Hoekman K, Löwik CW, Vermeij P, Bijvoet OL. Application of an in vitro model and a clinical protocol in the assessment of the potency of a new bisphosphonate. J Bone Miner Res. 1989 Oct;4(5):775–781. [PubMed]
  • Cecchini MG, Fleisch H. Bisphosphonates in vitro specifically inhibit, among the hematopoietic series, the development of the mouse mononuclear phagocyte lineage. J Bone Miner Res. 1990 Oct;5(10):1019–1027. [PubMed]
  • Miller SC, Jee WS. The effect of dichloromethylene diphosphonate, a pyrophosphate analog, on bone and bone cell structure in the growing rat. Anat Rec. 1979 Mar;193(3):439–462. [PubMed]
  • Plasmans CM, Jap PH, Kuijpers W, Slooff TJ. Influence of a diphosphonate on the cellular aspect of young bone tissue. Calcif Tissue Int. 1980;32(3):247–266. [PubMed]
  • Sato M, Grasser W. Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy. J Bone Miner Res. 1990 Jan;5(1):31–40. [PubMed]
  • Schenk R, Eggli P, Fleisch H, Rosini S. Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calcif Tissue Int. 1986 Jun;38(6):342–349. [PubMed]
  • Thompson DD, Seedor JG, Weinreb M, Rosini S, Rodan GA. Aminohydroxybutane bisphosphonate inhibits bone loss due to immobilization in rats. J Bone Miner Res. 1990 Mar;5(3):279–286. [PubMed]
  • Seedor JG, Quartuccio HA, Thompson DD. The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in rats. J Bone Miner Res. 1991 Apr;6(4):339–346. [PubMed]
  • Rouleau MF, Warshawsky H, Goltzman D. Parathyroid hormone binding in vivo to renal, hepatic, and skeletal tissues of the rat using a radioautographic approach. Endocrinology. 1986 Mar;118(3):919–931. [PubMed]
  • Kopriwa B. A comparison of various procedures for fine grain development in electron microscopic radioautography. Histochemistry. 1975 Aug 28;44(3):201–224. [PubMed]
  • Zambonin Zallone A, Teti A, Primavera MV. Isolated osteoclasts in primary culture: first observations on structure and survival in culture media. Anat Embryol (Berl) 1982 Dec;165(3):405–413. [PubMed]
  • Blair HC, Kahn AJ, Crouch EC, Jeffrey JJ, Teitelbaum SL. Isolated osteoclasts resorb the organic and inorganic components of bone. J Cell Biol. 1986 Apr;102(4):1164–1172. [PMC free article] [PubMed]
  • Arnett TR, Dempster DW. A comparative study of disaggregated chick and rat osteoclasts in vitro: effects of calcitonin and prostaglandins. Endocrinology. 1987 Feb;120(2):602–608. [PubMed]
  • Salomon Y, Londos C, Rodbell M. A highly sensitive adenylate cyclase assay. Anal Biochem. 1974 Apr;58(2):541–548. [PubMed]
  • Nicholson GC, Moseley JM, Sexton PM, Mendelsohn FA, Martin TJ. Abundant calcitonin receptors in isolated rat osteoclasts. Biochemical and autoradiographic characterization. J Clin Invest. 1986 Aug;78(2):355–360. [PMC free article] [PubMed]
  • Miyauchi A, Hruska KA, Greenfield EM, Duncan R, Alvarez J, Barattolo R, Colucci S, Zambonin-Zallone A, Teitelbaum SL, Teti A. Osteoclast cytosolic calcium, regulated by voltage-gated calcium channels and extracellular calcium, controls podosome assembly and bone resorption. J Cell Biol. 1990 Dec;111(6 Pt 1):2543–2552. [PMC free article] [PubMed]
  • Malgaroli A, Meldolesi J, Zallone AZ, Teti A. Control of cytosolic free calcium in rat and chicken osteoclasts. The role of extracellular calcium and calcitonin. J Biol Chem. 1989 Aug 25;264(24):14342–14347. [PubMed]
  • Zaidi M, Moonga B, Moss DW, MacIntyre I. Inhibition of osteoclastic acid phosphatase abolishes bone resorption. Biochem Biophys Res Commun. 1989 Feb 28;159(1):68–71. [PubMed]
  • Sietsema WK, Ebetino FH, Salvagno AM, Bevan JA. Antiresorptive dose-response relationships across three generations of bisphosphonates. Drugs Exp Clin Res. 1989;15(9):389–396. [PubMed]
  • Lin JH, Duggan DE, Chen IW, Ellsworth RL. Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals. Drug Metab Dispos. 1991 Sep-Oct;19(5):926–932. [PubMed]
  • Baron R, Neff L, Louvard D, Courtoy PJ. Cell-mediated extracellular acidification and bone resorption: evidence for a low pH in resorbing lacunae and localization of a 100-kD lysosomal membrane protein at the osteoclast ruffled border. J Cell Biol. 1985 Dec;101(6):2210–2222. [PMC free article] [PubMed]
  • Blair HC, Teitelbaum SL, Ghiselli R, Gluck S. Osteoclastic bone resorption by a polarized vacuolar proton pump. Science. 1989 Aug 25;245(4920):855–857. [PubMed]
  • Vänänen HK, Karhukorpi EK, Sundquist K, Wallmark B, Roininen I, Hentunen T, Tuukkanen J, Lakkakorpi P. Evidence for the presence of a proton pump of the vacuolar H(+)-ATPase type in the ruffled borders of osteoclasts. J Cell Biol. 1990 Sep;111(3):1305–1311. [PMC free article] [PubMed]
  • Chambers TJ, Darby JA, Fuller K. Mammalian collagenase predisposes bone surfaces to osteoclastic resorption. Cell Tissue Res. 1985;241(3):671–675. [PubMed]
  • Thompson DD, Seedor JG, Fisher JE, Rosenblatt M, Rodan GA. Direct action of the parathyroid hormone-like human hypercalcemic factor on bone. Proc Natl Acad Sci U S A. 1988 Aug;85(15):5673–5677. [PMC free article] [PubMed]
  • Sato M, Sardana MK, Grasser WA, Garsky VM, Murray JM, Gould RJ. Echistatin is a potent inhibitor of bone resorption in culture. J Cell Biol. 1990 Oct;111(4):1713–1723. [PMC free article] [PubMed]
  • Chappard D, Alexandre C, Palle S, Vico L, Morukov BV, Rodionova SS, Minaire P, Riffat G. Effects of a bisphosphonate (1-hydroxy ethylidene-1,1 bisphosphonic acid) on osteoclast number during prolonged bed rest in healthy humans. Metabolism. 1989 Sep;38(9):822–825. [PubMed]
  • Reitsma PH, Teitelbaum SL, Bijvoet OL, Kahn AJ. Differential action of the bisphosphonates (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) and disodium dichloromethylidene bisphosphonate (Cl2MDP) on rat macrophage-mediated bone resorption in vitro. J Clin Invest. 1982 Nov;70(5):927–933. [PMC free article] [PubMed]
  • Fast DK, Felix R, Dowse C, Neuman WF, Fleisch H. The effects of diphosphonates on the growth and glycolysis of connective-tissue cells in culture. Biochem J. 1978 Apr 15;172(1):97–107. [PMC free article] [PubMed]
  • Felix R, Bettex JD, Fleisch H. Effect of diphosphonates on the synthesis of prostaglandins in cultured calvaria cells. Calcif Tissue Int. 1981;33(5):549–552. [PubMed]
  • Stevenson PH, Stevenson JR. Cytotoxic and migration inhibitory effects of bisphosphonates on macrophages. Calcif Tissue Int. 1986 Apr;38(4):227–233. [PubMed]
  • Felix R, Guenther HL, Fleisch H. The subcellular distribution of [14C]dichloromethylenebisphosphonate and [14C]1-hydroxyethylidene-1,1-bisphosphonate in cultured calvaria cells. Calcif Tissue Int. 1984 Jan;36(1):108–113. [PubMed]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation


Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • Compound
    PubChem Compound links
  • MedGen
    Related information in MedGen
  • PubMed
    PubMed citations for these articles
  • Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...